Boehringer Ingelheim Reports 10% Revenue Growth Driven by Commercial and OEM Channels
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Boehringer Ingelheim reported total revenue of $30.6 million, marking 10% growth. The commercial channel generated $14.0 million, representing 17% growth, while the OEM channel contributed $16.6 million, growing 5%. Gross margin increased to 62%, compared to 56% in the prior year.
From fool.com
Why it matters
The company reported adjusted EBITDA of $5.1 million, up from $900,000 in the prior year. Growth in specific areas, such as Integrity revenue, which grew more than 30% year over year, indicates strong performance in key product lines.
From fool.com
Who's involved
- Boehringer IngelheimGerman pharmaceutical company that reported financial results
Keep exploring
The entities involved
-
Boehringer Ingelheim
German pharmaceutical company
-
Matthew Hall
American pediatrics researcher
Nothing else this week.